PMC:7156805 / 4685-6100 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"95","span":{"begin":107,"end":112},"obj":"Gene"},{"id":"96","span":{"begin":418,"end":423},"obj":"Gene"},{"id":"97","span":{"begin":724,"end":728},"obj":"Gene"},{"id":"98","span":{"begin":764,"end":768},"obj":"Gene"},{"id":"99","span":{"begin":861,"end":866},"obj":"Gene"},{"id":"100","span":{"begin":1028,"end":1034},"obj":"Gene"},{"id":"101","span":{"begin":1071,"end":1077},"obj":"Gene"},{"id":"102","span":{"begin":1160,"end":1165},"obj":"Gene"},{"id":"103","span":{"begin":1333,"end":1337},"obj":"Gene"},{"id":"104","span":{"begin":555,"end":560},"obj":"Disease"},{"id":"105","span":{"begin":977,"end":982},"obj":"Disease"}],"attributes":[{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"Gene:4790"},{"id":"A96","pred":"tao:has_database_id","subj":"96","obj":"Gene:7124"},{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"Gene:3552"},{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"Gene:3565"},{"id":"A99","pred":"tao:has_database_id","subj":"99","obj":"Gene:3605"},{"id":"A100","pred":"tao:has_database_id","subj":"100","obj":"Gene:3605"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"Gene:3605"},{"id":"A102","pred":"tao:has_database_id","subj":"102","obj":"Gene:51561"},{"id":"A103","pred":"tao:has_database_id","subj":"103","obj":"Gene:5141"},{"id":"A104","pred":"tao:has_database_id","subj":"104","obj":"MESH:D005334"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"MESH:D005334"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Drug class Mechanism of action Drug name Risk Comments/considerations∗\nClassic immunosuppressants\nInhibits NF-κB Corticosteroids Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure\nCalcineurin inhibitor Tacrolimus\nCyclosporine\n Antimetabolites Inhibits DNA replication Mycophenolate mofetil\nAzathioprine\nMethotrexate\nImmunomodulators\n Monoclonal antibodies TNF-α inhibition Infliximab Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Receptor fusion protein Etanercept\n Monoclonal antibodies Certolizumab\n Monoclonal antibodies Adalimumab\n IL receptor modulators IL inhibition Anakinra (IL-1)\n Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present\n Monoclonal antibodies Brodalumab (IL-17) Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Monoclonal antibodies Secukinumab (IL-17a)\n Monoclonal antibodies Ixekizumab (IL-17a)\n Monoclonal antibodies Ustekinumab (IL-12/23)\n Monoclonal antibodies Guselkumab (IL-23)\n Monoclonal antibodies Anti-CD20 antibody Rituximab Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure.\nPDE4 inhibition Apremilast Likely low risk Continue unless severe symptoms present"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T71","span":{"begin":314,"end":317},"obj":"Body_part"},{"id":"T72","span":{"begin":587,"end":594},"obj":"Body_part"},{"id":"T73","span":{"begin":677,"end":679},"obj":"Body_part"},{"id":"T74","span":{"begin":700,"end":702},"obj":"Body_part"},{"id":"T75","span":{"begin":724,"end":728},"obj":"Body_part"},{"id":"T76","span":{"begin":724,"end":726},"obj":"Body_part"},{"id":"T77","span":{"begin":764,"end":766},"obj":"Body_part"},{"id":"T78","span":{"begin":861,"end":863},"obj":"Body_part"},{"id":"T79","span":{"begin":1028,"end":1030},"obj":"Body_part"},{"id":"T80","span":{"begin":1071,"end":1073},"obj":"Body_part"},{"id":"T81","span":{"begin":1115,"end":1120},"obj":"Body_part"},{"id":"T82","span":{"begin":1115,"end":1117},"obj":"Body_part"},{"id":"T83","span":{"begin":1160,"end":1162},"obj":"Body_part"},{"id":"T84","span":{"begin":1200,"end":1208},"obj":"Body_part"}],"attributes":[{"id":"A71","pred":"fma_id","subj":"T71","obj":"http://purl.org/sig/ont/fma/fma74412"},{"id":"A72","pred":"fma_id","subj":"T72","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A73","pred":"fma_id","subj":"T73","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A74","pred":"fma_id","subj":"T74","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A76","pred":"fma_id","subj":"T76","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A77","pred":"fma_id","subj":"T77","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A78","pred":"fma_id","subj":"T78","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A81","pred":"fma_id","subj":"T81","obj":"http://purl.org/sig/ont/fma/fma86579"},{"id":"A82","pred":"fma_id","subj":"T82","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A83","pred":"fma_id","subj":"T83","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A84","pred":"fma_id","subj":"T84","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Drug class Mechanism of action Drug name Risk Comments/considerations∗\nClassic immunosuppressants\nInhibits NF-κB Corticosteroids Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure\nCalcineurin inhibitor Tacrolimus\nCyclosporine\n Antimetabolites Inhibits DNA replication Mycophenolate mofetil\nAzathioprine\nMethotrexate\nImmunomodulators\n Monoclonal antibodies TNF-α inhibition Infliximab Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Receptor fusion protein Etanercept\n Monoclonal antibodies Certolizumab\n Monoclonal antibodies Adalimumab\n IL receptor modulators IL inhibition Anakinra (IL-1)\n Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present\n Monoclonal antibodies Brodalumab (IL-17) Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Monoclonal antibodies Secukinumab (IL-17a)\n Monoclonal antibodies Ixekizumab (IL-17a)\n Monoclonal antibodies Ustekinumab (IL-12/23)\n Monoclonal antibodies Guselkumab (IL-23)\n Monoclonal antibodies Anti-CD20 antibody Rituximab Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure.\nPDE4 inhibition Apremilast Likely low risk Continue unless severe symptoms present"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T48","span":{"begin":111,"end":112},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"Drug class Mechanism of action Drug name Risk Comments/considerations∗\nClassic immunosuppressants\nInhibits NF-κB Corticosteroids Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure\nCalcineurin inhibitor Tacrolimus\nCyclosporine\n Antimetabolites Inhibits DNA replication Mycophenolate mofetil\nAzathioprine\nMethotrexate\nImmunomodulators\n Monoclonal antibodies TNF-α inhibition Infliximab Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Receptor fusion protein Etanercept\n Monoclonal antibodies Certolizumab\n Monoclonal antibodies Adalimumab\n IL receptor modulators IL inhibition Anakinra (IL-1)\n Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present\n Monoclonal antibodies Brodalumab (IL-17) Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Monoclonal antibodies Secukinumab (IL-17a)\n Monoclonal antibodies Ixekizumab (IL-17a)\n Monoclonal antibodies Ustekinumab (IL-12/23)\n Monoclonal antibodies Guselkumab (IL-23)\n Monoclonal antibodies Anti-CD20 antibody Rituximab Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure.\nPDE4 inhibition Apremilast Likely low risk Continue unless severe symptoms present"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T33","span":{"begin":107,"end":109},"obj":"Chemical"},{"id":"T36","span":{"begin":254,"end":263},"obj":"Chemical"},{"id":"T37","span":{"begin":264,"end":274},"obj":"Chemical"},{"id":"T38","span":{"begin":275,"end":287},"obj":"Chemical"},{"id":"T39","span":{"begin":314,"end":317},"obj":"Chemical"},{"id":"T40","span":{"begin":330,"end":343},"obj":"Chemical"},{"id":"T41","span":{"begin":365,"end":377},"obj":"Chemical"},{"id":"T42","span":{"begin":587,"end":594},"obj":"Chemical"},{"id":"T43","span":{"begin":595,"end":605},"obj":"Chemical"},{"id":"T44","span":{"begin":677,"end":679},"obj":"Chemical"},{"id":"T46","span":{"begin":680,"end":699},"obj":"Chemical"},{"id":"T47","span":{"begin":700,"end":702},"obj":"Chemical"},{"id":"T49","span":{"begin":724,"end":726},"obj":"Chemical"},{"id":"T51","span":{"begin":764,"end":766},"obj":"Chemical"},{"id":"T53","span":{"begin":861,"end":863},"obj":"Chemical"},{"id":"T55","span":{"begin":1028,"end":1030},"obj":"Chemical"},{"id":"T57","span":{"begin":1071,"end":1073},"obj":"Chemical"},{"id":"T59","span":{"begin":1115,"end":1117},"obj":"Chemical"},{"id":"T61","span":{"begin":1160,"end":1162},"obj":"Chemical"}],"attributes":[{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_141424"},{"id":"A34","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_25573"},{"id":"A35","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_1224"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_61049"},{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_4031"},{"id":"A39","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"},{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_168396"},{"id":"A41","pred":"chebi_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/CHEBI_44185"},{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_4875"},{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A45","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_90710"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A48","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A50","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A52","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A54","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A56","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A57","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A58","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A60","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A61","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A62","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Drug class Mechanism of action Drug name Risk Comments/considerations∗\nClassic immunosuppressants\nInhibits NF-κB Corticosteroids Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure\nCalcineurin inhibitor Tacrolimus\nCyclosporine\n Antimetabolites Inhibits DNA replication Mycophenolate mofetil\nAzathioprine\nMethotrexate\nImmunomodulators\n Monoclonal antibodies TNF-α inhibition Infliximab Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Receptor fusion protein Etanercept\n Monoclonal antibodies Certolizumab\n Monoclonal antibodies Adalimumab\n IL receptor modulators IL inhibition Anakinra (IL-1)\n Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present\n Monoclonal antibodies Brodalumab (IL-17) Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Monoclonal antibodies Secukinumab (IL-17a)\n Monoclonal antibodies Ixekizumab (IL-17a)\n Monoclonal antibodies Ustekinumab (IL-12/23)\n Monoclonal antibodies Guselkumab (IL-23)\n Monoclonal antibodies Anti-CD20 antibody Rituximab Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure.\nPDE4 inhibition Apremilast Likely low risk Continue unless severe symptoms present"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T28","span":{"begin":242,"end":253},"obj":"http://purl.obolibrary.org/obo/GO_0004723"},{"id":"T29","span":{"begin":242,"end":253},"obj":"http://purl.obolibrary.org/obo/GO_0004722"},{"id":"T30","span":{"begin":305,"end":329},"obj":"http://purl.obolibrary.org/obo/GO_0008156"},{"id":"T31","span":{"begin":314,"end":329},"obj":"http://purl.obolibrary.org/obo/GO_0006260"},{"id":"T32","span":{"begin":677,"end":688},"obj":"http://purl.obolibrary.org/obo/GO_0004896"}],"text":"Drug class Mechanism of action Drug name Risk Comments/considerations∗\nClassic immunosuppressants\nInhibits NF-κB Corticosteroids Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure\nCalcineurin inhibitor Tacrolimus\nCyclosporine\n Antimetabolites Inhibits DNA replication Mycophenolate mofetil\nAzathioprine\nMethotrexate\nImmunomodulators\n Monoclonal antibodies TNF-α inhibition Infliximab Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Receptor fusion protein Etanercept\n Monoclonal antibodies Certolizumab\n Monoclonal antibodies Adalimumab\n IL receptor modulators IL inhibition Anakinra (IL-1)\n Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present\n Monoclonal antibodies Brodalumab (IL-17) Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Monoclonal antibodies Secukinumab (IL-17a)\n Monoclonal antibodies Ixekizumab (IL-17a)\n Monoclonal antibodies Ustekinumab (IL-12/23)\n Monoclonal antibodies Guselkumab (IL-23)\n Monoclonal antibodies Anti-CD20 antibody Rituximab Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure.\nPDE4 inhibition Apremilast Likely low risk Continue unless severe symptoms present"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T10","span":{"begin":555,"end":560},"obj":"Phenotype"},{"id":"T11","span":{"begin":977,"end":982},"obj":"Phenotype"}],"attributes":[{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Drug class Mechanism of action Drug name Risk Comments/considerations∗\nClassic immunosuppressants\nInhibits NF-κB Corticosteroids Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure\nCalcineurin inhibitor Tacrolimus\nCyclosporine\n Antimetabolites Inhibits DNA replication Mycophenolate mofetil\nAzathioprine\nMethotrexate\nImmunomodulators\n Monoclonal antibodies TNF-α inhibition Infliximab Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Receptor fusion protein Etanercept\n Monoclonal antibodies Certolizumab\n Monoclonal antibodies Adalimumab\n IL receptor modulators IL inhibition Anakinra (IL-1)\n Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present\n Monoclonal antibodies Brodalumab (IL-17) Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Monoclonal antibodies Secukinumab (IL-17a)\n Monoclonal antibodies Ixekizumab (IL-17a)\n Monoclonal antibodies Ustekinumab (IL-12/23)\n Monoclonal antibodies Guselkumab (IL-23)\n Monoclonal antibodies Anti-CD20 antibody Rituximab Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure.\nPDE4 inhibition Apremilast Likely low risk Continue unless severe symptoms present"}

{"project":"LitCovid-sentences","denotations":[{"id":"T20","span":{"begin":0,"end":70},"obj":"Sentence"},{"id":"T21","span":{"begin":71,"end":97},"obj":"Sentence"},{"id":"T22","span":{"begin":98,"end":241},"obj":"Sentence"},{"id":"T23","span":{"begin":242,"end":274},"obj":"Sentence"},{"id":"T24","span":{"begin":275,"end":287},"obj":"Sentence"},{"id":"T25","span":{"begin":288,"end":351},"obj":"Sentence"},{"id":"T26","span":{"begin":352,"end":364},"obj":"Sentence"},{"id":"T27","span":{"begin":365,"end":377},"obj":"Sentence"},{"id":"T28","span":{"begin":378,"end":394},"obj":"Sentence"},{"id":"T29","span":{"begin":395,"end":569},"obj":"Sentence"},{"id":"T30","span":{"begin":570,"end":605},"obj":"Sentence"},{"id":"T31","span":{"begin":606,"end":641},"obj":"Sentence"},{"id":"T32","span":{"begin":642,"end":675},"obj":"Sentence"},{"id":"T33","span":{"begin":676,"end":729},"obj":"Sentence"},{"id":"T34","span":{"begin":730,"end":825},"obj":"Sentence"},{"id":"T35","span":{"begin":826,"end":991},"obj":"Sentence"},{"id":"T36","span":{"begin":992,"end":1035},"obj":"Sentence"},{"id":"T37","span":{"begin":1036,"end":1078},"obj":"Sentence"},{"id":"T38","span":{"begin":1079,"end":1124},"obj":"Sentence"},{"id":"T39","span":{"begin":1125,"end":1166},"obj":"Sentence"},{"id":"T40","span":{"begin":1167,"end":1332},"obj":"Sentence"},{"id":"T41","span":{"begin":1333,"end":1415},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Drug class Mechanism of action Drug name Risk Comments/considerations∗\nClassic immunosuppressants\nInhibits NF-κB Corticosteroids Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure\nCalcineurin inhibitor Tacrolimus\nCyclosporine\n Antimetabolites Inhibits DNA replication Mycophenolate mofetil\nAzathioprine\nMethotrexate\nImmunomodulators\n Monoclonal antibodies TNF-α inhibition Infliximab Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Receptor fusion protein Etanercept\n Monoclonal antibodies Certolizumab\n Monoclonal antibodies Adalimumab\n IL receptor modulators IL inhibition Anakinra (IL-1)\n Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present\n Monoclonal antibodies Brodalumab (IL-17) Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops\n Monoclonal antibodies Secukinumab (IL-17a)\n Monoclonal antibodies Ixekizumab (IL-17a)\n Monoclonal antibodies Ustekinumab (IL-12/23)\n Monoclonal antibodies Guselkumab (IL-23)\n Monoclonal antibodies Anti-CD20 antibody Rituximab Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure.\nPDE4 inhibition Apremilast Likely low risk Continue unless severe symptoms present"}